Therapeutic targeting of cell cycle checkpoint aberrations in pancreatic cancer: personalised medicine in action

胰腺癌细胞周期检查点畸变的治疗靶向：个性化医疗在行动

• 批准号: nhmrc : 1081312
• 负责人: Dr Andrew Burgess
• 金额: $ 42.3万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/therapeutic-targeting-cell-medicine-action/518799
• 关键词: Therapeutic; targeting; cell; cycle; checkpoint

Less than 5% of people with pancreatic cancer (PC) survive 5 years, and the odds of patients beating this disease have remained unchanged for 50 years. Consequently, there is an urgent need to develop novel treatment approaches for this highly aggressive cancer. Our study aims to define novel therapeutic strategies for PC utilising specific anti-proliferative therapies and a personalised “companion biomarker” directed strategy.

不到5%的胰腺癌患者存活5年，而患者战胜这种疾病的几率50年来一直保持不变。因此，迫切需要为这种高度侵袭性的癌症开发新的治疗方法。我们的研究旨在定义PC的新治疗策略，利用特定的抗增殖疗法和个性化的“伴生生物标记物”指导策略。